Clinical Trials Logo

Combination Chemotherapy clinical trials

View clinical trials related to Combination Chemotherapy.

Filter by:
  • None
  • Page 1

NCT ID: NCT04152057 Recruiting - Breast Cancer Clinical Trials

Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer

Start date: November 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This study was designed to evaluate the efficacy and safety of pyrotinib combined with albumin paclitaxel and trastuzumab in the treatment of Her2-positive early or locally advanced breast cancer, and to explore RCB scores and TILs expression and other related molecular markers for pyrrole the efficacy of the treatment with pyrotinib.

NCT ID: NCT03201146 Recruiting - Lung Cancer Clinical Trials

Apatinib Combine With Platinumā€Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC

Start date: June 27, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and clinical activity of Apatinib in combination with AP(Pemetrexed/Carboplatin) or AC(Pemetrexed/Carboplatin) as first-line chemotherapy in subjects with advanced EGFR wild type non-squamous non-small cell lung cancer(NSCLC).

NCT ID: NCT00504192 Completed - Efficacy Clinical Trials

A Phase II Study of Gemcitabine With Oxaliplatin as First Line Chemotherapy in Advanced Biliary Tract Cancer

Start date: September 2006
Phase: Phase 2
Study type: Interventional

The role of systemic chemotherapy in advanced biliary tract cancer (BTC) is known to be very limited although various single-agent or combination therapies had been tested. However, there is a possibility that palliative chemotherapy induce prolong survival and improve quality of life in advanced BTC based on several studies. A GERCOR study showed the promising result of gemcitabine in combination with oxaliplatin as first line chemotherapy in advanced BTC. Therefore, this phase II trial was planned to investigate efficacy and toxicity of combination chemotherapy with gemcitabine and dose adjusted oxaliplatin in patients with inoperable BTC in Korea.